Fusion Antibodies (LSE:FAB) EBIT per Share : £-0.04 (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies EBIT per Share?

Fusion Antibodies's EBIT per Share for the six months ended in Mar. 2024 was £-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was £-0.04.

During the past 3 years, the average EBIT per Share Growth Rate was 5.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Fusion Antibodies's EBIT per Share or its related term are showing as below:

LSE:FAB' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -122.4 Med: -3.7 Max: 9.1
Current: 5.8

During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Fusion Antibodies was 9.10% per year. The lowest was -122.40% per year. And the median was -3.70% per year.

LSE:FAB's 3-Year EBIT Growth Rate is ranked better than
53.2% of 1280 companies
in the Biotechnology industry
Industry Median: 3.6 vs LSE:FAB: 5.80

Fusion Antibodies's EBIT for the six months ended in Mar. 2024 was £-0.87 Mil.

Fusion Antibodies EBIT per Share Historical Data

The historical data trend for Fusion Antibodies's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies EBIT per Share Chart

Fusion Antibodies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EBIT per Share

Get a 7-Day Free Trial

-0.05

-0.11

-0.04

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
EBIT per Share	Get a 7-Day Free Trial												-0.03	-0.05	-0.06	-0.03	-0.01

Fusion Antibodies EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Fusion Antibodies's EBIT per Share for the fiscal year that ended in Mar. 2024 is calculated as

	EBIT per Share		(A: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.284	/	55.556
=	-0.04

Fusion Antibodies's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.867	/	95.366
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.04

Fusion Antibodies (LSE:FAB) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Fusion Antibodies EBIT per Share Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Antibodies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL

Website

https://www.fusionantibodies.com

Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor • 10-21-2022